News and Events

News
Upcoming Events
Past Events

Cardiovascular Systems Enrolls First Patient in ORBIT II Coronary Clinical Trial Posted: Wednesday, 26th of May 2010, 10:59:44 AM

Pivotal Study Evaluating the Clinical Benefits of Treating Calcified Coronary Lesions with the Diamondback 360° System

CSI Completes Enrollment in COMPLIANCE 360° Clinical Trial Posted: Tuesday, 25th of May 2010, 09:45:24 AM

Study Evaluates Clinical Benefits of Treating Above-the-Knee Peripheral Arterial Disease with Diamondback 360° System

CSI Completes Enrollment in CALCIUM 360° Clinical Trial Posted: Friday, 30th of April 2010, 11:27:26 AM

Study Evaluates Clinical Benefits of Treating Peripheral Arterial Disease Behind and Below the Knee with Diamondback 360° System

CSI Receives Undconditional FDA Approval for ORBIT II Coronary Clinical Trial Posted: Friday, 30th of April 2010, 11:14:37 AM

Pivotal Study Will Evaluate Clinical Benefits of Treating Calcified Coronary Lesions with Diamondback 360° System

The COMPLIANCE 360° Trial Posted: Friday, 9th of April 2010, 10:45:25 AM CONTINUE READING

First Patient Enrolled in COMPLIANCE 360° Clinical Trial Posted: Tuesday, 5th of January 2010, 01:19:07 AM

First Patient Enrolled in COMPLIANCE 360° Clinical Trial

CSI Reports Two-Year Data Showing Durable Outcomes in Patients Treated with Diamondback 360° PAD System Posted: Tuesday, 5th of January 2010, 12:59:19 AM

CSI Reports Two Year Data Showing Durable Outcomes in Patients Treated with Diamondback 360° PAD System

ISET 2010 When: Tuesday, 5th of January 2010, 01:35:17 AM Where: Westin Diplomat Hotel, Hollywood 33176, Florida

The ISET conference will take place on January 17-21, 2010 in Hollywood, FL.

Careers

Contact

Privacy

Site Map

CSI Headquarters
651 Campus Drive

P: 651.259.1600

F: 612.677.3355
St. Paul, MN 55112

877.CSI.0360

E: generalinquiries@csi360.com

CSI Customer Service
F: 877.274.0901
E: customerservice@csi360.com

Disclosure: The Diamondback 360^® PAD System is a percutaneous orbital atherectomy system indicated for use as therapy in patients with occlusive atherosclerotic disease in peripheral arteries and stenotic material from artificial arteriovenous dialysis fistulae. The System is contraindicated for use in coronary arteries, bypass grafts, stents, or where thrombus or dissections are present. Although the incidence of adverse events is rare, potential events that can occur with atherectomy include: pain, hypotension, CVA/TIA, death, dissection, perforation, distal embolization, thrombus formation, hematuria, abrupt or acute vessel closure, or arterial spasm.

Web Design : WebBizIdeas.com